Management of Severe Paranoia, Delusions, and Agitation in Dementia

Investigation and Assessment

Pain assessment and management is a major contributor to behavioral disturbances and must be addressed before considering medication adjustments, according to Praxis Medical Insights 1
Checking for urinary tract infection and pneumonia is crucial as these are the most common infections triggering agitation in dementia, as reported by Annals of Emergency Medicine 2, 3
Assessing for constipation and urinary retention is significant as both worsen behavioral symptoms, noted by Annals of Emergency Medicine 2 and Praxis Medical Insights 1
Reviewing all medications for anticholinergic effects is necessary as these worsen agitation and cognitive function, stated by Annals of Emergency Medicine 2, 3
Checking for dehydration and electrolyte disturbances is important, as highlighted by Annals of Emergency Medicine 2, 3
Assessing hearing and vision problems is vital as sensory impairments increase confusion and fear, according to Praxis Medical Insights 1

The American Geriatrics Society recommends avoiding benzodiazepines for routine use in agitated dementia due to risks of tolerance, addiction, cognitive impairment, and paradoxical agitation 1
Tapering and discontinuing clonazepam over 2-4 weeks while monitoring closely for withdrawal symptoms is advised, as suggested by Praxis Medical Insights 1
Citalopram 10mg daily or sertraline 25-50mg daily can be considered as adjunctive treatment for persistent severe agitation, according to Praxis Medical Insights 1
SSRIs significantly reduce overall neuropsychiatric symptoms, agitation, and depression in dementia patients, as noted by Praxis Medical Insights 1
Assessing response within 4 weeks using quantitative measures like the Cohen-Mansfield Agitation Inventory or NPI-Q is recommended, according to Praxis Medical Insights 1

Brexpiprazole carries a black box warning for increased mortality risk in elderly patients with dementia-related psychosis, as reported by Praxis Medical Insights 1
All antipsychotics increase mortality risk 1.6-1.7 times higher than placebo in this population, according to Praxis Medical Insights 1
Additional risks include cardiovascular effects, cerebrovascular adverse reactions, falls, and metabolic changes, as stated by Praxis Medical Insights 1
Documenting the discussion and decision-making process, including why benefits are expected to outweigh risks, is essential, as highlighted by American Journal of Psychiatry 4 and Praxis Medical Insights 1